News & Events

ASU embarks on next phase of an effort to rapidly assess radiation dose

October 6, 2011

TEMPE, Ariz.--Arizona State University has announced today it is entering the next phase of a multi-million, multi-institutional research project to develop technologies that would rapidly measure an individual’s level of exposure to radiation in the event of a radiological or nuclear incident.  The project will enter a $5 million contract option as part of a potential $35.44 million project funded by the U.S. Department of Health and Human Services’ Biomedical Advanced Research and...

LaBaer awarded Health Care Hero for discoveries in breast cancer detection and treatment

August 19, 2011

Eighteenth century poet Novalis said, “A hero is one who knows how to hang on one minute longer.” That sort of dogged determination to uncover early indictors of disease earned Joshua LaBaer, M.D., Ph.D., of the Biodesign Institute at Arizona State University, the 2011 Phoenix Business Journal’s Health Care Hero in the researcher/innovator category. The annual award honors exemplary performance in the Phoenix health care industry. Award recipients were announced at a breakfast at the...

LaBaer named Health Care Heroes finalist for discoveries in breast cancer detection and treatment

June 23, 2011

Joshua LaBaer, M.D., Ph.D., of the Biodesign Institute at Arizona State University, has been selected as one of three finalists for the Phoenix Business Journal’s Health Care Hero award in the researcher/innovator category. The annual award honors exemplary performance in the Phoenix health care industry. Award recipients will be announced at a breakfast at the Arizona Biltmore Resort on Aug. 18. Two years ago, LaBaer, a medical oncologist and research scientist, was recruited from Harvard...

Study identifies new genetic signatures of breast cancer drug resistance

January 10, 2011

A new study conducted by Josh LaBaer’s research team in the Biodesign Institute at Arizona State University has pinpointed more than 30 breast cancer gene targets ---including several novel genes---that are involved in drug resistance to a leading chemotherapy treatment. The results of the study may one day aid in the treatment of the one in ten U.S. women who will develop breast cancer, by empowering physicians with a more personalized approach to therapy as well as a new tool for the...

Scientists discover powerful biomarker panel for the early detection of breast cancer

December 16, 2010

In the war on cancer, perhaps there is nothing more powerful in a physician’s arsenal than early detection. Despite recent advances in early detection and treatment, breast cancer remains a common and significant health problem in the United States and worldwide. Approximately one in ten women will get breast cancer in their lifetime and more than half of women with late stage cancer (II and III) have no cure or effective therapeutic available. Using a new, powerful method for rapidly...

Blood relations: new study explores early detection of ovarian cancer

June 16, 2010

Despite many research advances, ovarian cancer remains lethal in a majority of cases, due to late diagnosis of the disease. In a new study, Dr. Joshua LaBaer of the Biodesign Institute at Arizona State University, along with Arturo Ramirez and Paul Lampe, researchers at the Fred Hutchinson Cancer Research Center in Seattle, used  a novel method for identifying biomarkers—proteins in blood that can identify ovarian cancer before symptoms appear. The work, which appeared recently in the...